The SARC028 trial using the anti-PD-1 antibody pembrolizumab in patients with advanced sarcoma reported encouraging outcomes in patients with some specific subtypes of STS, while the total objective response rate was only 18% (7/40). The gene discussed is PDCD1; the disease is telomere syndrome.